Abstract_vorhanden_with_categories_v08_for_homepage_06.xls

2nd World Conference on Magic Bullets (Ehrlich II) Name Presentation title
(in alphabetical order)
Cardiovascular and related drugs
Xenon: a magic bullet for the treatment of acute ischemia? CARDIAC TAMPONADE SECONDARY TO SLINGSHOT METAL DART : A RETROSPECTIVE REVIEW OF CASES Cell-free octameric hemoglobin as a blood substitute WATER CHANNEL PROTEINS (AQUAPORINS): FROM THEIR DISCOVERY IN 1985 IN CLUJ-NAPOCA, ROMANIA (BY THE USE OF A DOPING NMR METHOD AND SPECIFIC LABELING) TO THE USE OF THEIR INHIBITORS AS MAGIC BULLETS Novel targets and magic bullets for treating cardiovascular disease THE EFFECT OF 4HZ (30DB) INFRASOUND ON HEART MUSCLE CONTRACTILITY Antithrombotics that do not induce bleeding: the “holy grail” found by interfering with von Willebrand factor Targeting Cellular Mechanisms with Natural Antioxidants from Red Palm Oil in order to enhance Cardioprotection Antioxidant Supplementation Impacts upon Electronegative Low Density Lipoprotein Plasma Levels and Cardiovascular Risk Verapamil Reverts Acute Renal Functional Impairment Induced by Angiotensin II Converting Enzyme Inhibitors Increased repolarization reserve as a new anti-arrhythmic principle Pharmacokinetic-Pharmacodynamic modeling of calcium channel blockers in animal models of hypertension.
Genetic variant of KIF6 predicts both increased risk for coronary events and greater benefit from statin therapy: an overview of genetic studies of the CARE, WOSCOPS, and PROVE IT - TIMI 22 trials The ACE-inhibitor: Magic bullet from myocardium to endothelium Nifedipine, the most citated, studied, experienced and debated ca-antagonist: where has it gone? Extremely high natriuretic effect of vasotocin analogues in rats Innovation in Anticoagulation: The Discovery and Development of Novel Small Molecule Coagulation Inhibitors as New Treatment Option for Thromboembolic Diseases An enzymatic approach for developing heparan sulfate-based drugs Pharmacokinetic-Pharmacodynamic Modeling of Aliskiren Effects on Biomarkers of the Renin-Angiotensin System in Humans Central sympatholytic and anti-arrhythmic effects of 5-HT1A agonists Racial disparity in stroke risk factors: the Berlin–Ibadan experience; a retrospective study Digoxin plasma levels in patients using four common therapeutic schedules Systemic Immunosuppressive Therapy with Oral Sirolimus After Bare Metal Stent Implantation: The Missing Alternative in the Prevention of Coronary Restenosis After Percutaneous Coronary Interventions.
Rimonabant, first CB1 receptor antagonist, a potential magic bullet to reduce cardiometabolic risk in patients with abdominal obesity 2nd World Conference on Magic Bullets (Ehrlich II) Name Presentation title
(in alphabetical order)
Cardiovascular and related drugs
A New Strategy to Inhibit Foam Cell Formation in Atherosclerosis Using the Soluble Immunoadhesion CD68-Fc Evolution and perspectives of chronic heart failure therapy from pathophysiologic basis Can Cardiovascular Drugs Influence Clinical outcome in CABG patients Hyaluronan Mixed Esters of Butyric and Retinoic Acids: Multicomponent-Multitarget Drugs with Differentiating and Paracrine Logics for Cardiovascular Repair with Human Mesenchymal Stem Cells Cardiac Hormones: Magic Bullets for the Treatment of Congestive Heart Failure, Renal Failure and Cancer Diabetes and Metabolic Diseases
Pro-atherogenic and pro-inflammatory alterations in mononuclear cells populations induced by oxidized LDL and high glucose levels in type 2 diabetic patients. Anti-inflammatory drugs, an alternative? ADIPOPHARMACOLOGY: A NEW WAY TO SEARCH FOR MAGIC BULLETS A potential molecular link for metabolic stress and carcinogenesis: AMP-activated protein kinase Protection to whole body and other severely damaged cellular entities in mice pretreated with a combination of signature molecules isolated from Podophyllum hexandrum and exposed to whole body lethal radiation Selective inhibition of signal peptide-dependent cotranslational translocation by the cyclopeptolide CAM741 The Utility of the Cholestanol:Cholesterol Ratio in Predicting LDL-Cholesterol response to Atorvastatin 80 mg: A paradigm for individualized lipid-lowering therapy The Importance of Appropriate Animal Models for Evaluating Agents for Proliferative Retinopathy: Failure of Combretastatin to inhibit Diabetes-Like Proliferative Retinopathy in the Galactose-Fed Dog Targeting Cell Cycle Progression by Troglitazone.
Towards a Magic Bullet for the Metabolic Syndrome – Use of the Ginkgo Biloba Extract Specific Inhibitors of the Cyclic Nucleotide Phosphodiesterases PDE2 and PDE4 Overcome In Vitro and In Vivo Angiogenesis Bromocriptine Effect in Cardiorenal Damage in Patients with Type 2 Diabetes Mellitus Perfluorocarbons(PFC) as universal remedial of free radical homeostasis at the wide spectrum of various metabolic disorders Multiple Pharmacologic Approach to atherosclerosis Diabetes foot ulcers: A novel treatment strategy (Documental Based Approach) Effect of Insulin Resistance on In-Stent Restenosis after Coronary Stenting in Type 2 Diabetic Patients Combined Therapy with Pitavastatin And Eicosapentaenoic Acid Improve Platelet Activation Markers in Hyperlipidemic Patients with Type 2 Diabetes Mellitus Dipeptidyl peptidase 4 inhibitors: a new class of oral agents for the treatment of type 2 diabetes mellitus The clinical role of the statins in surgical neurosciences 2nd World Conference on Magic Bullets (Ehrlich II) Name Presentation title
(in alphabetical order)
Diabetes and Metabolic Diseases
The Acute Effects of Statins in an Experimental Model of Renal Ischemia-Reperfusion Injury Targeting Dexamethasone-Loaded anti-E-selectin Liposomes Prevents Glomerulonephritis Progression: The Potential of Vascular Bed-Specific Drug Delivery A new focus on atherosclerosis treatment: transialidase from Trypanosoma cruzi as an anti-proliferative drug.
Suppression of Membrane Microvesiculation – a Possible Anticoagulant and Anti-Tumor Progression Effect of Heparin Developing an enzymatic approach to synthesize heparin-based drugs

Source: http://www.ehrlich-2008.org/06_Cardiovascular_Diabetes.pdf